Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Summary

This is a single dose, open label study in adult male subjects with cystic fibrosis to investigate the pharmacokinetics, safety and tolerability of GLPG2737.

Timeline

Start

2017-06-28

Primary completion

2017-08-16

Completion

2017-08-16

Drugs

Indications